LIMR Expands Licensing and Commercialization Relationship with Rockland Immunochemicals

Monday, October 15, 2012

Lankenau Institute for Medical Research (LIMR) has expanded its licensing and commercialization relationship with Rockland Immunochemicals, Inc. through its business development subsidiary LIMR Development, Inc. (LDI) and consultant Carl Leighton of Wildwood Capital. According to the new agreement, Rockland will exclusively market established LIMR technologies including CellCountEZ^®, OxPhos^™, RadDose^™, and Intracellular ThiolEZ^™.

Rockland Immunochemicals is a biotechnology company manufacturing antibodies and antibody-based tools for basic research, diagnostic assay development and preclinical studies. George Prendergast, PhD, President and CEO of LIMR stated: “We have been very pleased with our partnership with Rockland and are looking forward to continued success within this expanded relationship.”

"LIMR's independent research encompassing cancer and inflammation elegantly enhances Rockland's antibody portfolio and technology platform. It is my belief that the new products included in our expanded licensing and commercialization agreement will enhance our ability to bring unique scientific opportunities to the global research community," commented James Fendrick, President and CEO of Rockland Immunochemicals.

The additional product lines include the CellCountEZ^® assay which measures metabolically live cells to quantify cell viability, toxicity, and proliferation. The OxPhos^™ assay determines the cellular glutathione recycling capacity in tissue culture or whole blood, providing insight into oxidative stress during the aging process, antioxidant levels upon delivery of chemotherapy regime, and toxicology. RadDose^™ is a diagnostic tool that measures ionizing radiation dose rates, while the Intracellular ThiolEZ^™ assay is used to evaluate total intracellular thiols, including glutathione and cysteine, as a means of investigating the aging, oxidative stress, antioxidant, chemotherapy response, and toxicology processes.

About LIMR Development, Inc.

LIMR Development, Inc. (LDI) is the business development subsidiary of Lankenau Institute for Medical Research (LIMR). LDI promotes the research conducted by LIMR scientists through technology development and commercialization to create new diagnostic, prognostic and therapeutic tools for clinical and research use. LDI’s product and service information can be found on www.limrdev.com.

Founded in 1927, LIMR is an independent, non-profit biomedical research center located in suburban Philadelphia on the campus of the Lankenau Medical Center. The Institute’s faculty and staff are dedicated to advancing the understanding of diseases such as cancer, heart disease and diabetes. Please visit www.limr.org for additional information about Lankenau Institute for Medical Research.

About Rockland Immunochemicals

Rockland Immunochemicals has supported the biopharma and diagnostic industries with antibodies and antibody based tools^™ for basic research, assay development and preclinical studies for 50 years. With facilities in Pennsylvania, Rockland manufactures over 10,000 products ideally suited for integration into various assays performed on different platforms including western blot, immunohistochemistry (IHC), immunofluorescence (IF), microscopy, ELISA and FLOW cytometry. Additional information about Rockland Immunochemicals’ products and services can be found on the company’s web site at http://www.rockland-inc.com/.